New York, New York (PRWEB) February 23, 2015
A Risperdal lawsuit (http://www.risperdallawsuit2014.com/) that alleges the atypical antipsychotic can cause gynecomastia, or male breast growth, is now in the hands of the jury, Bernstein Liebhard LLP reports. According to court documents, the case is the first to involve gynecomastia to go to trial in the mass tort proceeding underway in Pennsylvanias Court of Common Pleas, where the Firm is representing numerous clients who are also alleged to have developed female-like breasts due to their use of Risperdal. Testimony has now wrapped up in the proceeding, and the parties delivered their closing arguments on Friday, February 20th. (Case No. A-196444)
We have been following this case closely, including Fridays closing argument, says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. “It is interesting to note that court records indicate the closings placed much emphasis on expert testimony, which for the Plaintiff included a former FDA commissioner who testified that the Defendants did not add information about the association between Risperdal and gynecomastia in boys until 2006, even though Johnson & Johnson and Janssen had allegedly been promoting the use of the drug in children for years. Bernstein Liebhard LLP continues to provide legal consultations to men and boys who allegedly developed gynecomastia, or male breast growth, due to their use of Risperdal.
Bernstein Liebhard LLP notes that the Risperdal lawsuit at trial is one of nearly 1,300 currently pending in the Philadelphia Court of Common Pleas. According to court documents, the case was filed on behalf of a severely autistic man who began taking Risperdal as a boy in 2002 and allegedly developed size 44 DD breasts due to its use. At that time, the drug hadnt been approved for any pediatric indications, which would not occur until 2006. Like others pending in the proceeding, the complaint asserts that Johnson & Johnson and its Janssen Pharmaceuticals unit improperly promoted the medication for use in children long before pediatric indications were approved by the U.S. Food & Drug Administration. (In Re: Risperdal Litigation, Case Number 100300296)
We are looking forward to the jurys decision in this case, as this is a bellwether trial and could provide insight into how juries will rule in similar lawsuits involving Risperdal and gynecomastia, says Bernstein Liebhard LLP.
Victims of gynecomastia allegedly related to the use of Risperdal may be able to recover compensation for medical bills, lost wages, pain and suffering and other damages. To learn more about filing a Risperdal lawsuit, please visit Bernstein Liebhard LLPs website. For a free case review, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $ 3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016